دورية أكاديمية
أعرض في EDS

Formulation, Optimization and Evaluation of Cytarabine-Loaded Iron Oxide Nanoparticles: From In Vitro to In Vivo Evaluation of Anticancer Activity.

التفاصيل البيبلوغرافية
العنوان: Formulation, Optimization and Evaluation of Cytarabine-Loaded Iron Oxide Nanoparticles: From In Vitro to In Vivo Evaluation of Anticancer Activity.
المؤلفون: Fule R; Department of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Besa, Nagpur 440036, Maharashtra, India., Kaleem M; Department of Pharmacology, Dadasaheb Balpande College of Pharmacy, Besa, Nagpur 440036, Maharashtra, India.; Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Asar TO; Department of Biology, College of Science and Arts at Alkamil, University of Jeddah, Jeddah 23218, Saudi Arabia., Rashid MA; Department of Pharmaceutics, College of Pharmacy, King Khalid University, Al Faraa, Abha 62529, Saudi Arabia., Shaik RA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Eid BG; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Nasrullah MZ; Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia., Ahmad A; Health Information Technology Department, Faculty of Applied Studies, King Abdulaziz University, Jeddah 21589, Saudi Arabia.; Pharmacovigilance and Medication Safety Unit, Center of Research Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 22252, Saudi Arabia., Kazmi I; Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
المصدر: Nanomaterials (Basel, Switzerland) [Nanomaterials (Basel)] 2022 Dec 30; Vol. 13 (1). Date of Electronic Publication: 2022 Dec 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101610216 Publication Model: Electronic Cited Medium: Print ISSN: 2079-4991 (Print) Linking ISSN: 20794991 NLM ISO Abbreviation: Nanomaterials (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2011]-
مستخلص: Innovative drug delivery systems based on iron oxide nanoparticles (INPs) has generated a lot of interest worldwide and have prime biomedical benefits in anticancer therapy. There are still issues reported regarding the stability, absorption, and toxicity of iron oxide nanoparticles (INPs) when administered due to its rapid surface oxidation and agglomeration with blood proteins. To solve this problem, we have synthesized trehalose-coated stabilized iron oxide nanoparticles (TINPs) by a co-precipitation technique. The surface coating of INPs with trehalose helps to improve the stability, prevents protein binding, and increase absorption uptake inside the body. Developed TINPs was then loaded with anticancer drug cytarabine by chemical crosslinking encapsulation method using suitable solvent. Engineered cytarabine-loaded trehalose-coated stabilized iron oxide nanoparticles (CY-TINPs) were optimized for particle size, zeta potential (-13.03 mV), and solid-state characterization such as differential scanning calorimetry (DSC), X-ray powder diffraction (XRD), and transmission electron microscope (TEM) studies. The particle size of 50 nm was achieved for developed CY-TINPs. The developed CY-TINPs was further evaluated for in vitro cell line investigations which confirmed potential cytotoxic activity. Developed CY-TINPs show remarkable enhancement in in vivo pharmacokinetic parameters C max as 425.26 ± 2.11 and AUC 0-72 as 11,546.64 ± 139.82 as compared to pure drug. Compared to traditional drug delivery, the CY-TINPs formulation can effectively delay release, improve bioavailability, and boost cytotoxic activity against tumors.
References: J Nanobiotechnology. 2018 Sep 19;16(1):71. (PMID: 30231877)
Biomaterials. 2003 Nov;24(25):4551-7. (PMID: 12950997)
Dev Reprod. 2014 Dec;18(4):197-212. (PMID: 25949190)
Eur J Med Chem. 2014 Sep 12;84:718-30. (PMID: 25064349)
Nano Rev. 2010;1:. (PMID: 22110864)
Environ Mol Mutagen. 2015 Mar;56(2):125-48. (PMID: 25209650)
Eur J Med Chem. 2013 Jun;64:99-110. (PMID: 23644193)
Int J Pharm. 2016 Feb 29;499(1-2):280-294. (PMID: 26746801)
J Control Release. 2004 Nov 5;100(1):53-61. (PMID: 15491810)
Int J Mol Sci. 2022 Oct 02;23(19):. (PMID: 36232989)
Gan. 1975 Dec;66(6):719-20. (PMID: 1225724)
Nanomaterials (Basel). 2020 Aug 11;10(8):. (PMID: 32796757)
Croat Med J. 2014 Jun 1;55(3):195-205. (PMID: 24891278)
Avian Dis. 1992 Oct-Dec;36(4):1022-7. (PMID: 1485851)
Gels. 2022 Jul 19;8(7):. (PMID: 35877535)
J Biomol Struct Dyn. 2012;30(4):394-406. (PMID: 22686514)
Clin Chem. 2006 Apr;52(4):601-23. (PMID: 16484333)
Br Med J. 1959 Apr 11;1(5127):947-9. (PMID: 13638595)
Mater Sci Eng C Mater Biol Appl. 2017 Sep 1;78:1023-1034. (PMID: 28575936)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 May-Jun;7(3):446-57. (PMID: 25377422)
Biomed Res Int. 2013;2013:942916. (PMID: 24027766)
Int J Cell Biol. 2010;2010:214074. (PMID: 20182529)
J Biomed Mater Res B Appl Biomater. 2014 May;102(4):860-8. (PMID: 24458920)
J Colloid Interface Sci. 2017 Apr 15;492:157-166. (PMID: 28086118)
Proc Math Phys Eng Sci. 2018 Mar;474(2211):20170845. (PMID: 29662344)
Pharmaceutics. 2022 Mar 03;14(3):. (PMID: 35335935)
Methods Mol Biol. 2011;731:237-45. (PMID: 21516412)
Int J Pharm. 2015 Dec 30;496(1):137-56. (PMID: 26471056)
J Nanobiotechnology. 2014 Oct 04;12:38. (PMID: 25277602)
Rejuvenation Res. 2010 Oct;13(5):589-98. (PMID: 21142669)
Pharmaceutics. 2021 Apr 07;13(4):. (PMID: 33916981)
Redox Rep. 2009;14(3):102-8. (PMID: 19490751)
Colloids Surf B Biointerfaces. 2017 Feb 1;150:261-270. (PMID: 28029547)
J Biomed Mater Res A. 2008 Jun 1;85(3):582-7. (PMID: 17806122)
Int J Mol Sci. 2012;13(9):11610-11642. (PMID: 23109874)
معلومات مُعتمدة: IFPIP:1054-166-1443 King Abdulaziz University
فهرسة مساهمة: Keywords: bioavailability studies; cell line studies; cytarabine; iron oxide nanoparticle; trehalose
تواريخ الأحداث: Date Created: 20230108 Latest Revision: 20230111
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9824610
DOI: 10.3390/nano13010175
PMID: 36616087
قاعدة البيانات: MEDLINE
الوصف
تدمد:2079-4991
DOI:10.3390/nano13010175